In contrast, 80–90% of ER+ tumors are also AR-positive (AR+) and associated with favorable prognoses (e.g., longer relapse-free survival, lower tumor grade, and smaller tumor size) [97,98], which has been confirmed in several meta-analyses [99,100,101]. The gene discussed is ESR1; the disease is neoplasm.